Based on these data we sought to re-assess the prognostic significance of BIRC5 gene expression in CD138-purified MM cells from a cohort of 1093 previously untreated patients and to pre-clinically evaluate YM155 for its therapeutic potential in MM. This evidence concerns the gene SDC1 and Miyoshi myopathy.